These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 37460463)

  • 61. miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma.
    Park SE; Kim W; Hong JY; Kang D; Park S; Suh J; You D; Park YY; Suh N; Hwang JJ; Kim CS
    Sci Rep; 2022 Mar; 12(1):3537. PubMed ID: 35241735
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity.
    Miheecheva N; Postovalova E; Lyu Y; Ramachandran A; Bagaev A; Svekolkin V; Galkin I; Zyrin V; Maximov V; Lozinsky Y; Isaev S; Ovcharov P; Shamsutdinova D; Cheng EH; Nomie K; Brown JH; Tsiper M; Ataullakhanov R; Fowler N; Hsieh JJ
    Cell Rep; 2022 Aug; 40(7):111180. PubMed ID: 35977503
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Future perspectives for mTOR inhibitors in renal cell cancer treatment.
    Czarnecka AM; Kornakiewicz A; Lian F; Szczylik C
    Future Oncol; 2015; 11(5):801-17. PubMed ID: 25757683
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
    Liu W; Ren D; Xiong W; Jin X; Zhu L
    J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ultrasound Molecular Imaging of Renal Cell Carcinoma: VEGFR targeted therapy monitored with VEGFR1 and FSHR targeted microbubbles.
    Ingels A; Leguerney I; Cournède PH; Irani J; Ferlicot S; Sébrié C; Benatsou B; Jourdain L; Pitre-Champagnat S; Patard JJ; Lassau N
    Sci Rep; 2020 Apr; 10(1):7308. PubMed ID: 32355171
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors.
    Simon AG; Esser LK; Ellinger J; Branchi V; Tolkach Y; Müller S; Ritter M; Kristiansen G; Muders MH; Mayr T; Toma MI
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2255-2265. PubMed ID: 32533404
    [TBL] [Abstract][Full Text] [Related]  

  • 67. HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma.
    Lai XM; Liu SY; Tsai YT; Sun GH; Chang SY; Huang SM; Cha TL
    Oncotarget; 2017 Jul; 8(30):49713-49724. PubMed ID: 28572533
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.
    Elaidi R; Harbaoui A; Beuselinck B; Eymard JC; Bamias A; De Guillebon E; Porta C; Vano Y; Linassier C; Debruyne PR; Gross-Goupil M; Ravaud A; Aitelhaj M; Marret G; Oudard S
    Ann Oncol; 2015 Feb; 26(2):378-85. PubMed ID: 25467013
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.
    Tsuzuki T; Sassa N; Shimoyama Y; Morikawa T; Shiroki R; Kuroda M; Fukatsu A; Kuwahara K; Yoshino Y; Hattori R; Gotoh M
    Histopathology; 2014 Mar; 64(4):484-93. PubMed ID: 24274732
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib.
    Vanmechelen M; Lambrechts D; Van Brussel T; Verbiest A; Couchy G; Schöffski P; Dumez H; Debruyne PR; Lerut E; Machiels JP; Richard V; Albersen M; Verschaeve V; Oudard S; Méjean A; Wolter P; Zucman-Rossi J; Beuselinck B
    Clin Genitourin Cancer; 2019 Apr; 17(2):e235-e246. PubMed ID: 30527746
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 72. MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.
    Kovacova J; Poprach A; Buchler T; Cho WC; Slaby O
    Clin Chem Lab Med; 2018 Aug; 56(9):1426-1431. PubMed ID: 29451857
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
    Bridgeman VL; Wan E; Foo S; Nathan MR; Welti JC; Frentzas S; Vermeulen PB; Preece N; Springer CJ; Powles T; Nathan PD; Larkin J; Gore M; Vasudev NS; Reynolds AR
    Mol Cancer Ther; 2016 Jan; 15(1):172-83. PubMed ID: 26487278
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma.
    Xu C; Li Y; Su W; Wang Z; Ma Z; Zhou L; Zhou Y; Chen J; Jiang M; Liu M
    Aging (Albany NY); 2022 Sep; 14(17):6917-6935. PubMed ID: 36057262
    [TBL] [Abstract][Full Text] [Related]  

  • 75. First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma.
    Serzan MT; Xu W; Berg SA
    Hematol Oncol Clin North Am; 2023 Oct; 37(5):951-964. PubMed ID: 37258355
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
    Beuselinck B; Verbiest A; Couchy G; Job S; de Reynies A; Meiller C; Albersen M; Verkarre V; Lerut E; Méjean A; Patard JJ; Laguerre B; Rioux-Leclercq N; Schöffski P; Oudard S; Zucman-Rossi J
    Acta Oncol; 2018 Apr; 57(4):498-508. PubMed ID: 29095068
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Optimal management of metastatic renal cell carcinoma: current status.
    Escudier B; Albiges L; Sonpavde G
    Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
    [TBL] [Abstract][Full Text] [Related]  

  • 78. HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma.
    Xu X; Zhang S; Wang Y; Zhu Y; Wang J; Guo J
    Cancer Med; 2023 May; 12(9):10512-10525. PubMed ID: 37031459
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.
    Verbiest A; Lambrechts D; Van Brussel T; Couchy G; Wozniak A; Méjean A; Lerut E; Oudard S; Verkarre V; Job S; de Reynies A; Machiels JP; Patard JJ; Zucman-Rossi J; Beuselinck B
    Clin Genitourin Cancer; 2018 Aug; 16(4):266-273. PubMed ID: 29503246
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
    Blesius A; Beuselinck B; Chevreau C; Ravaud A; Rolland F; Oudard S; Escudier B
    Clin Genitourin Cancer; 2013 Jun; 11(2):128-33. PubMed ID: 23332872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.